Berlin – A common oral bacterium, often associated with gum disease, may play a significant role in the development and spread of breast cancer, according to new research published in January 2026. The study, conducted by researchers at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy, reveals a concerning link between Fusobacterium nucleatum and the progression of this disease. This finding adds to a growing body of evidence connecting the oral microbiome to cancer development, building on previous associations with colorectal and other cancers.
Fusobacterium nucleatum is a frequently found inhabitant of the human mouth, well-known for its contribution to the pathogenesis of periodontal disease. Epidemiological studies have suggested a correlation between periodontal conditions and an increased risk of several cancers, including breast cancer, hinting at a possible indirect connection between the prevalence of F. Nucleatum and cancer initiation. Still, establishing a direct causal link has proven challenging – until now. Researchers have been able to demonstrate this direct influence more clearly in the context of colorectal cancer, and this new study extends those findings to breast cancer.
The Link Between Oral Health and Breast Cancer
The research, published in Cell Communication and Signaling, details how F. Nucleatum can travel through the bloodstream and colonize breast tissue. Once established, the bacterium triggers inflammation and other changes that create a more favorable environment for cancer cells to thrive. This process isn’t simply about the presence of the bacteria; it’s about how it interacts with the body’s own cells and systems.
The study found that colonization with F. Nucleatum in healthy mice led to the development of metaplastic lesions, accompanied by inflammation, DNA damage, and increased cell proliferation. Metaplastic breast cancer is a rare and aggressive subtype, and this finding suggests a potential pathway for the bacterium to contribute to the development of particularly challenging cases. Further experiments with breast tumor-bearing mice showed that the introduction of F. Nucleatum via the bloodstream accelerated tumor growth and increased the likelihood of metastasis – the spread of cancer to other parts of the body.
How F. Nucleatum Impacts Cancer Cells
The researchers discovered that F. Nucleatum doesn’t just passively reside in breast tissue; it actively interacts with cancer cells. Exposure to the bacterium increased proliferation, migration, and self-renewal in both breast cancer cells and non-tumorigenic breast epithelial cells. Importantly, the study also revealed that F. Nucleatum enhances chemoresistance, making cancer cells less responsive to chemotherapy treatments. This internalization occurs through a process dependent on Gal-GalNAc, a sugar residue.
Interestingly, the study highlighted a particular vulnerability in breast cancer cells carrying BRCA1 mutations. These cells exhibited a greater accumulation of Gal-GalNAc on their surface, making them more susceptible to F. Nucleatum internalization. BRCA1 is a gene associated with DNA repair, and mutations in this gene significantly increase the risk of breast and ovarian cancer. The increased internalization of the bacterium in BRCA1-mutated cells suggests that individuals with these mutations may be at a higher risk of developing or experiencing more aggressive breast cancer if exposed to F. Nucleatum. This finding implicates impaired DNA damage and repair pathways as key mechanisms by which the bacterium promotes cancer progression.
The Role of Gal-GalNAc
Gal-GalNAc, or N-acetylgalactosamine, appears to be a crucial factor in the interaction between F. Nucleatum and breast cancer cells. The study demonstrated that F. Nucleatum utilizes this sugar residue to bind to and enter cells. The increased presence of Gal-GalNAc on the surface of BRCA1-mutated cells explains their heightened susceptibility to infection. This discovery opens up potential avenues for therapeutic intervention, such as developing strategies to block the interaction between the bacterium and cancer cells by targeting Gal-GalNAc.
Implications for Prevention and Treatment
The findings from Johns Hopkins suggest that maintaining good oral hygiene could be a preventative measure against breast cancer, particularly for individuals with BRCA1 mutations or other genetic predispositions. Although more research is needed to fully understand the complex interplay between the oral microbiome and breast cancer, these results underscore the importance of comprehensive health practices.
“This research highlights a previously underappreciated connection between oral health and breast cancer,” explains Dr. Leanna McArthur, a leading oncologist not involved in the study. “It suggests that addressing periodontal disease and maintaining a healthy oral microbiome could be a valuable addition to existing breast cancer prevention strategies.”
Future Research Directions
Researchers are now focusing on several key areas. One priority is to investigate the prevalence of F. Nucleatum in breast tissue samples from patients with and without BRCA1 mutations. This will facilitate to determine the extent to which the bacterium contributes to breast cancer development in different populations. Another area of focus is the development of targeted therapies that can disrupt the interaction between F. Nucleatum and cancer cells, potentially improving treatment outcomes. Further studies are also planned to explore the potential role of the oral microbiome in other types of cancer.
What This Means for Patients
While these findings are promising, it’s important to emphasize that this research is still in its early stages. It does not indicate that everyone with F. Nucleatum in their mouth will develop breast cancer. However, it does suggest that maintaining good oral hygiene – including regular brushing, flossing, and dental check-ups – is a prudent step for overall health and may contribute to reducing cancer risk. Individuals with a family history of breast cancer, particularly those with known BRCA1 mutations, should discuss these findings with their healthcare providers.
The study reinforces the growing understanding of the microbiome’s influence on overall health. The intricate relationship between bacteria, the immune system, and cancer development is becoming increasingly clear, paving the way for innovative prevention and treatment strategies. The research team at Johns Hopkins plans to continue investigating the role of F. Nucleatum and other oral bacteria in cancer progression, with the ultimate goal of developing more effective therapies for this devastating disease.
The next step in this research will be clinical trials to assess the efficacy of interventions targeting F. Nucleatum in breast cancer patients. Researchers anticipate these trials will begin within the next two years, offering a potential new avenue for treatment and prevention. Stay informed about the latest developments in breast cancer research by consulting with your healthcare provider and following reputable medical news sources.
What are your thoughts on this new research? Share your comments below, and please share this article with anyone who might discover it helpful.
Keep reading